Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.53 |
| ▸ | RORC | P51449 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4727085 | 0.88 | TACR1 (0.53) | TACR1RORCMAPTP2RY14GPR119 | |
| SCHEMBL16874572 | 0.88 | RORC (0.46) | TACR1RORCGPR119PDE4BUSP30 | |
| SCHEMBL19355948 | 0.88 | RORC (0.46) | TACR1RORCGPR119PDE4BUSP30 | |
| SCHEMBL16874709 | 0.88 | RORC (0.46) | TACR1RORCGPR119PDE4BUSP30 | |
| SCHEMBL16874574 | 0.88 | RORC (0.46) | TACR1RORCGPR119PDE4BUSP30 | |
| SCHEMBL528239 | 0.87 | TACR1 (0.52) | TACR1RORCMAPTP2RY14GPR119 | |
| SCHEMBL24832885 | 0.87 | RORC (0.46) | TACR1RORCMAPTGPR119PDE4B | |
| SCHEMBL24494926 | 0.87 | RORC (0.48) | TACR1RORCGPR119PDE4BUSP30 | |
| SCHEMBL24494925 | 0.87 | RORC (0.48) | TACR1RORCGPR119PDE4BUSP30 | |
| SCHEMBL31341952 | 0.87 | RORC (0.48) | TACR1RORCGPR119PDE4BUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | PFIZER INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | EFREMOV IVAN | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | PAICS, TMBIM6, ABCG2 | TACR1 1595/4885RORC 1322/4885MAPT 2472/4885 |
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | AZI2, PAICS, UGT2B7 | TACR1 1612/4885RORC 797/4885MAPT 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.